John W. Walsh Alpha-1 Home Infusion Act of 2023

John W. Walsh Alpha-1 Home Infusion Act of 2023

This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.

Bill 118 HR 4438, also known as the John W. Walsh Alpha-1 Home Infusion Act of 2023, aims to improve access to home infusion therapy for individuals with Alpha-1 Antitrypsin Deficiency. This genetic disorder can lead to serious lung and liver complications, and home infusion therapy can help manage symptoms and improve quality of life for patients.

The bill proposes to establish a demonstration program within Medicare to provide coverage for home infusion therapy services specifically for individuals with Alpha-1 Antitrypsin Deficiency. This program would allow patients to receive necessary medications and treatments in the comfort of their own homes, rather than having to travel to a healthcare facility for infusion therapy.

Additionally, the bill includes provisions to ensure that healthcare providers are properly trained and certified to administer home infusion therapy for Alpha-1 patients. This would help ensure the safety and effectiveness of the treatments provided in the home setting. Overall, the John W. Walsh Alpha-1 Home Infusion Act of 2023 seeks to improve access to care and quality of life for individuals with Alpha-1 Antitrypsin Deficiency by expanding coverage for home infusion therapy services through Medicare.